The global stem cells market is expected to grow at an incredible CAGR of 25.5% from 2015 to 2022 and reach a market value of US$297 billion by 2022. The emergence of Induced Pluripotent Stem cells as an alternative to ESCs (embryonic stem cells), growth of developing markets, and evolution of new stem cell therapies represent promising growth opportunities for leading players in this sector.Due to the increased funding from Government and Private sector and rising global awareness about stem cell therapies and research are the main factors which are driving this market. A surge in therapeutic research activities funded by governments across the world has immensely propelled the global stem cells market. However, the high cost of stem cell treatment and stringent government regulations against the harvesting of stem cells are expected to restrain the growth of the global stem cells market. Whereas the Europe Stem cell market is estimated to grow at a CAGR of 9.45% by the end of the forecast period of 2018- 2026. The market is chiefly progressing due to increasing R&D investments in adult stem cell research in the region, ease of administration and the growing incidences of chronic disease due to the changing lifestyles of the population.The countries analyzed in the Europe Stem cell market are UK, France, Germany, Spain, Italy and rest of Europe. Most of these countries have a stable economic environment, enabling their population to spend more on their health. In this report, the Europe stem cell market has been segmented based on technology, product and applications. At present, the regenerative medicine application accounts for a high revenue share. Because of their use in regenerative therapies, stem cells are increasingly finding applications in the fields of neurological and hematological disorders, and in areas such as organ transplants, Crohn’s disease, systemic lupus, and infertility.